Efficacy of Shinabro in Hand Osteoarthritis
Primary Purpose
Hand Osteoarthritis
Status
Completed
Phase
Phase 2
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Shinbaro
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Hand Osteoarthritis focused on measuring osteoarthritis, hand, Shinbaro, GCSB-5
Eligibility Criteria
Inclusion Criteria:
- Age of 40 years or older
- Osteoarthritis according to ACR 1990 criteria
- Mean joint visual analog pain score (VAS) > 30mm in the preceding 48 hours
- Patients who are will to participate
Exclusion Criteria:
- Any prior surgery of hand joints
- prior history of Shinbaro use
- Intra-articular injection of glucocorticosteroid or hyaluronic acid in the preceding 3 months
- Pregnancy or active breast feeding
- Prior hypersensitivity reaction to herbal medications
- AST or ALT elevation > 3 of upper normal limit
- GRF (MDRD) < 30 mg/min/1.73m2
- Nephrotic syndrome, other signficant kidney disease
- Patients who seem not to tolerate the study at investigator's discretion
- Patients who refuse to participate
Sites / Locations
- Seoul National Univ. Bundang Hospital
- Seoul National University Hospital
- SMG-SNU Boramae Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Placebo Comparator
Active Comparator
Arm Label
Placebo
Shinbaro
Arm Description
Placebo 2 capsules, twice daily, for 12 weeks.
Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
Outcomes
Primary Outcome Measures
AUSCAN Pain Change at 4 Weeks From Baseline
Change in AUSCAN pain score at 4 weeks from baseline = Pain at 4 weeks (0-100) - Pain at baseline (0-100).
AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).
Negative value means improvement from baseline
Positive value means deterioration from baseline
Secondary Outcome Measures
AUSCAN Pain Score at 8 Weeks From Baseline
Change in AUSCAN pain score at 8 weeks from baseline = Pain at 8 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).
Negative value means improvement from baseline
Positive value means deterioration from baseline
AUSCAN Pain Score at 12 Weeks From Baseline
Change in AUSCAN pain score at 12 weeks from baseline = Pain at 12 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).
Negative value means improvement from baseline
Positive value means deterioration from baseline
AUSCAN Pain Score at 16 Weeks From Baseline
Change in AUSCAN pain score at 16 weeks from baseline = Pain at 16 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).
Negative value means improvement from baseline
Positive value means deterioration from baseline
AUSCAN Stiffness at 4 Weeks Change From Baseline
Change in AUSCAN stiffness score at 4 weeks from baseline = Stiffness at 4 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).
Negative value means improvement from baseline
Positive value means deterioration from baseline
AUSCAN Stiffness at 8 Weeks Change From Baseline
Change in AUSCAN stiffness score at 8 weeks from baseline = Stiffness at 8 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).
Negative value means improvement from baseline
Positive value means deterioration from baseline
AUSCAN Stiffness at 12 Weeks Change From Baseline
Change in AUSCAN stiffness score at 12 weeks from baseline = Stiffness at 12 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).
Negative value means improvement from baseline
Positive value means deterioration from baseline
AUSCAN Stiffness at 16 Weeks Change From Baseline
Change in AUSCAN stiffness score at 16 weeks from baseline = Stiffness at 16 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).
Negative value means improvement from baseline
Positive value means deterioration from baseline
AUSCAN Function Change at 4 Weeks From Baseline
Change in AUSCAN function score at 4 weeks from baseline = Function score at 4 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).
Negative value means improvement from baseline
Positive value means deterioration from baseline
AUSCAN Function Change at 8 Weeks From Baseline
Change in AUSCAN function score at 8 weeks from baseline = Function score at 8 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).
Negative value means improvement from baseline
Positive value means deterioration from baseline
AUSCAN Function Change at 12 Weeks From Baseline
Change in AUSCAN function score at 12 weeks from baseline = Function score at 12 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).
Negative value means improvement from baseline
Positive value means deterioration from baseline
AUSCAN Function Change at 16 Weeks From Baseline
Change in AUSCAN function score at 16 weeks from baseline = Function score at 16 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).
Negative value means improvement from baseline
Positive value means deterioration from baseline
Patient Global Assessment, Change From Baseline
Change in Patient global assessment (PGA) at 4 weeks from baseline = PGA at 4 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline
Patient Global Assessment, Change From Baseline
Change in Patient global assessment (PGA) at 8 weeks from baseline = PGA at 8 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline
Patient Global Assessment, Change From Baseline
Change in Patient global assessment (PGA) at 12 weeks from baseline = PGA at 12 weeks (0-100)- PGA score at baseline (0-100). GPA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline
Patient Global Assessment, Change From Baseline
Change in Patient global assessment (PGA) at 16 weeks from baseline = PGA at 16 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline
Physician Global Assessment, Change From Baseline
Change in Physician global assessment (PhGA) at 4 weeks from baseline = PhGA at 4 weeks (0-100)- PhGA score at baseline (0-100). GPA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline
Physician Global Assessment, Change From Baseline
Change in Physician global assessment (PhGA) at 8 weeks from baseline = PhGA at 8 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline
Physician Global Assessment, Change From Baseline
Change in Physician global assessment (PhGA) at 12 weeks from baseline = PhGA at 12 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline
Physician Global Assessment, Change From Baseline
Change in Physician global assessment (PhGA) at 16 weeks from baseline = PhGA at 16 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline
Tender Joint Count, Change From Baseline
Change in Tender joint count (TJC) at 4 weeks from baseline = TJC at 4 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline
Tender Joint Count, Change From Baseline
Change in Tender joint count (TJC) at 8 weeks from baseline = TJC at 8 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline
Tender Joint Count, Change From Baseline
Change in Tender joint count (TJC) at 12 weeks from baseline = TJC at 12 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline
Tender Joint Count, Change From Baseline
Change in Tender joint count (TJC) at 16 weeks from baseline = TJC at 16 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline
Swollen Joint Count, Change From Baseline
Change in Swollen joint count (SJC) at 4 weeks from baseline = SJC at 4 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline
Swollen Joint Count, Change From Baseline
Change in Swollen joint count (SJC) at 8 weeks from baseline = SJC at 8 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline
Swollen Joint Count, Change From Baseline
Change in Swollen joint count (SJC) at 12 weeks from baseline = SJC at 12 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline
Swollen Joint Count, Change From Baseline
Change in Swollen joint count (SJC) at 16 weeks from baseline = SJC at 16 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline
Acetaminophen Rescue
yes = AAP rescue use, no = no AAP rescue use
Acetaminophen Rescue
yes = AAP rescue use, no = no AAP rescue use
Acetaminophen Rescue
yes = AAP rescue use, no = no AAP rescue use
Acetaminophen Rescue
yes = AAP rescue use, no = no AAP rescue use
Number of OMERACT-OARSI Responder
Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment
Number of OMERACT-OARSI Responder
Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment
Number of OMERACT-OARSI Responder
Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment
Number of OMERACT-OARSI Responder
Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment
Full Information
NCT ID
NCT01910116
First Posted
July 22, 2013
Last Updated
November 16, 2015
Sponsor
Seoul National University Hospital
Collaborators
Green Cross Corporation
1. Study Identification
Unique Protocol Identification Number
NCT01910116
Brief Title
Efficacy of Shinabro in Hand Osteoarthritis
Official Title
Treatment Efficacy of 'Shinbaro Capsule' in the Treatment of Hand Osteoarthritis: Randomized, Double-blinded, Placebo-controlled, Multicenter Investigator Initiated Trial.
Study Type
Interventional
2. Study Status
Record Verification Date
August 2015
Overall Recruitment Status
Completed
Study Start Date
September 2013 (undefined)
Primary Completion Date
November 2014 (Actual)
Study Completion Date
November 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Seoul National University Hospital
Collaborators
Green Cross Corporation
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
GCSB-5 ("Shinbaro capsule"), is a mixture of 6 oriental herbs that have anti-inflammatory and analgesic effects along with an excellent safety profile. This study is aimed at investigating efficacy of Shinbaro in the treatment of hand osteoarthritis which needs a long term treatment in a placebo controlled, double-blind randomized trial.
Detailed Description
Osteoarthritis (OA) as a common musculoskeletal disease affects more than 30% of the elderly population. It frequently involves knees, hips, spines and hands. In hands, the distal and proximal interphalangeal and the first carpometacarpal joints are affected, leading often to significant disability and limitation in the daily activity. The chronic progressive nature of the disease requires a life-long treatment. The mainstay treatment of hand OA targets pain control. Non-steroidal anti-inflammatory drugs (NSAIDs) are often used. However, they are frequently associated with significant gastrointestinal side effects including gastritis, peptic ulcer diseases, and bleeding, especially with long term use. Further, they do not ameliorate pain completely, requiring additional medications such as acetaminophen or opioid-based analgesics.
Shibaro is a mixture of purified oriental herbs consisting of Ledebouriellae Radix, Achyranthis Radix, Acanthopanacis Cortex, Cibotii Rhizoma, Glycine Semen, and Eucommiae Cortex. These herbs have been used for the treatment of diverse inflammatory conditions in Chines traditional medicine. All 6 herbs show an excellent safety profile and their anti-inflammatory and analgesic effects have been studied in both animals and humans. As such, given the excellent safety profile, anti-inflammatory and analgesic effects, Shinbaro might be ideal in the treatment of OA.
This study will investigate the efficacy and safety of Shinbaro in the treatment of hand OA in a placebo-controlled, randomized, double-blind, multi-center trial.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hand Osteoarthritis
Keywords
osteoarthritis, hand, Shinbaro, GCSB-5
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
220 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo 2 capsules, twice daily, for 12 weeks.
Arm Title
Shinbaro
Arm Type
Active Comparator
Arm Description
Shinbaro, 2 capsules (300mg), twice daily, for 12 weeks
Intervention Type
Drug
Intervention Name(s)
Shinbaro
Other Intervention Name(s)
GCSB-5
Intervention Description
GCSB-5 (Shinbaro) is a mixture of six purified oriental herb extracts in a fixed ratio, namely, Saposhnikovia divaricata Schischk, Glycine max Merrill, Cibotium barometz J. Smith, Eucommia ulmoides Oliver, Achyranthes japonica Nakai, and Acanthopanax sessiliflorus Seem
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
The study medication and placebo were identical in appearance.
Primary Outcome Measure Information:
Title
AUSCAN Pain Change at 4 Weeks From Baseline
Description
Change in AUSCAN pain score at 4 weeks from baseline = Pain at 4 weeks (0-100) - Pain at baseline (0-100).
AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).
Negative value means improvement from baseline
Positive value means deterioration from baseline
Time Frame
Baseline and 4 weeks
Secondary Outcome Measure Information:
Title
AUSCAN Pain Score at 8 Weeks From Baseline
Description
Change in AUSCAN pain score at 8 weeks from baseline = Pain at 8 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).
Negative value means improvement from baseline
Positive value means deterioration from baseline
Time Frame
Baseline, 8 weeks
Title
AUSCAN Pain Score at 12 Weeks From Baseline
Description
Change in AUSCAN pain score at 12 weeks from baseline = Pain at 12 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).
Negative value means improvement from baseline
Positive value means deterioration from baseline
Time Frame
Baseline, 12 weeks
Title
AUSCAN Pain Score at 16 Weeks From Baseline
Description
Change in AUSCAN pain score at 16 weeks from baseline = Pain at 16 weeks (0-100)- Pain at baseline (0-100). AUSCAN Pain scale ranges from 0 (no pain) to 100 (worst possible pain).
Negative value means improvement from baseline
Positive value means deterioration from baseline
Time Frame
Baseline and 16 weeks
Title
AUSCAN Stiffness at 4 Weeks Change From Baseline
Description
Change in AUSCAN stiffness score at 4 weeks from baseline = Stiffness at 4 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).
Negative value means improvement from baseline
Positive value means deterioration from baseline
Time Frame
Baseline and 4 weeks
Title
AUSCAN Stiffness at 8 Weeks Change From Baseline
Description
Change in AUSCAN stiffness score at 8 weeks from baseline = Stiffness at 8 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).
Negative value means improvement from baseline
Positive value means deterioration from baseline
Time Frame
baseline and 8 weeks
Title
AUSCAN Stiffness at 12 Weeks Change From Baseline
Description
Change in AUSCAN stiffness score at 12 weeks from baseline = Stiffness at 12 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).
Negative value means improvement from baseline
Positive value means deterioration from baseline
Time Frame
Basline and 12 weeks
Title
AUSCAN Stiffness at 16 Weeks Change From Baseline
Description
Change in AUSCAN stiffness score at 16 weeks from baseline = Stiffness at 16 weeks (0-100)- Stiffness at baseline (0-100). AUSCAN Stiffness scale ranges from 0 (no stiffness) to 100 (worst possible stiffness).
Negative value means improvement from baseline
Positive value means deterioration from baseline
Time Frame
Baseline, 16 weeks
Title
AUSCAN Function Change at 4 Weeks From Baseline
Description
Change in AUSCAN function score at 4 weeks from baseline = Function score at 4 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).
Negative value means improvement from baseline
Positive value means deterioration from baseline
Time Frame
Basline and 4 weeks
Title
AUSCAN Function Change at 8 Weeks From Baseline
Description
Change in AUSCAN function score at 8 weeks from baseline = Function score at 8 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).
Negative value means improvement from baseline
Positive value means deterioration from baseline
Time Frame
Baseline and 8 weeks
Title
AUSCAN Function Change at 12 Weeks From Baseline
Description
Change in AUSCAN function score at 12 weeks from baseline = Function score at 12 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).
Negative value means improvement from baseline
Positive value means deterioration from baseline
Time Frame
Baseline and 12 weeks
Title
AUSCAN Function Change at 16 Weeks From Baseline
Description
Change in AUSCAN function score at 16 weeks from baseline = Function score at 16 weeks (0-100)- Function score at baseline (0-100). AUSCAN Function score scale ranges from 0 (no functional limitation) to 100 (worst possible functional limitation).
Negative value means improvement from baseline
Positive value means deterioration from baseline
Time Frame
Baseline and 16 weeks
Title
Patient Global Assessment, Change From Baseline
Description
Change in Patient global assessment (PGA) at 4 weeks from baseline = PGA at 4 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline
Time Frame
Baseline and 4 weeks
Title
Patient Global Assessment, Change From Baseline
Description
Change in Patient global assessment (PGA) at 8 weeks from baseline = PGA at 8 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline
Time Frame
Baseline and 8 weeks
Title
Patient Global Assessment, Change From Baseline
Description
Change in Patient global assessment (PGA) at 12 weeks from baseline = PGA at 12 weeks (0-100)- PGA score at baseline (0-100). GPA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline
Time Frame
Baseline and 12 weeks
Title
Patient Global Assessment, Change From Baseline
Description
Change in Patient global assessment (PGA) at 16 weeks from baseline = PGA at 16 weeks (0-100)- PGA score at baseline (0-100). PGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline
Time Frame
Baseline and 16 weeks
Title
Physician Global Assessment, Change From Baseline
Description
Change in Physician global assessment (PhGA) at 4 weeks from baseline = PhGA at 4 weeks (0-100)- PhGA score at baseline (0-100). GPA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline
Time Frame
baseline and 4 weeks
Title
Physician Global Assessment, Change From Baseline
Description
Change in Physician global assessment (PhGA) at 8 weeks from baseline = PhGA at 8 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline
Time Frame
Baseline and 8 weeks
Title
Physician Global Assessment, Change From Baseline
Description
Change in Physician global assessment (PhGA) at 12 weeks from baseline = PhGA at 12 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline
Time Frame
Baseline and 12 weeks
Title
Physician Global Assessment, Change From Baseline
Description
Change in Physician global assessment (PhGA) at 16 weeks from baseline = PhGA at 16 weeks (0-100)- PhGA score at baseline (0-100). PhGA scale ranges from 0 (excellent condition) to 100 (worst possible worse possible condition).
Negative value means improvement from baseline
Positive value means deterioration from baseline
Time Frame
Baseline and 16 weeks
Title
Tender Joint Count, Change From Baseline
Description
Change in Tender joint count (TJC) at 4 weeks from baseline = TJC at 4 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline
Time Frame
Baseline and 4 weeks
Title
Tender Joint Count, Change From Baseline
Description
Change in Tender joint count (TJC) at 8 weeks from baseline = TJC at 8 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline
Time Frame
Baseline and 8 weeks
Title
Tender Joint Count, Change From Baseline
Description
Change in Tender joint count (TJC) at 12 weeks from baseline = TJC at 12 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline
Time Frame
Baseline and 12 weeks
Title
Tender Joint Count, Change From Baseline
Description
Change in Tender joint count (TJC) at 16 weeks from baseline = TJC at 16 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline
Time Frame
Baseline and 16 weeks
Title
Swollen Joint Count, Change From Baseline
Description
Change in Swollen joint count (SJC) at 4 weeks from baseline = SJC at 4 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline
Time Frame
Baseline and 4 weeks
Title
Swollen Joint Count, Change From Baseline
Description
Change in Swollen joint count (SJC) at 8 weeks from baseline = SJC at 8 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline
Time Frame
Baseline and 8 weeks
Title
Swollen Joint Count, Change From Baseline
Description
Change in Swollen joint count (SJC) at 12 weeks from baseline = SJC at 12 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline
Time Frame
Baseline and 12 weeks
Title
Swollen Joint Count, Change From Baseline
Description
Change in Swollen joint count (SJC) at 16 weeks from baseline = SJC at 16 weeks - TJC at baseline..
Negative value means improvement from baseline
Positive value means deterioration from baseline
Time Frame
Baseline and 16 weeks
Title
Acetaminophen Rescue
Description
yes = AAP rescue use, no = no AAP rescue use
Time Frame
Baseline 4 weeks
Title
Acetaminophen Rescue
Description
yes = AAP rescue use, no = no AAP rescue use
Time Frame
4 weeks and 8 weeks
Title
Acetaminophen Rescue
Description
yes = AAP rescue use, no = no AAP rescue use
Time Frame
8 weeks and 12 weeks
Title
Acetaminophen Rescue
Description
yes = AAP rescue use, no = no AAP rescue use
Time Frame
12 weeks and 16 weeks
Title
Number of OMERACT-OARSI Responder
Description
Outcome Measures in Rheumatology-Osteoarthritis Research Society International (OMERACT-OARSI) Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment
Time Frame
Baseline and 4 weeks
Title
Number of OMERACT-OARSI Responder
Description
Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment
Time Frame
Baseline and 8 weeks
Title
Number of OMERACT-OARSI Responder
Description
Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment
Time Frame
Baseline and 12 weeks
Title
Number of OMERACT-OARSI Responder
Description
Number of patients who met OMERACT-OARSI criteria = significant clinical improvement in osteoarthritis symptom after treatment
Time Frame
Baselie and 16 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age of 40 years or older
Osteoarthritis according to ACR 1990 criteria
Mean joint visual analog pain score (VAS) > 30mm in the preceding 48 hours
Patients who are will to participate
Exclusion Criteria:
Any prior surgery of hand joints
prior history of Shinbaro use
Intra-articular injection of glucocorticosteroid or hyaluronic acid in the preceding 3 months
Pregnancy or active breast feeding
Prior hypersensitivity reaction to herbal medications
AST or ALT elevation > 3 of upper normal limit
GRF (MDRD) < 30 mg/min/1.73m2
Nephrotic syndrome, other signficant kidney disease
Patients who seem not to tolerate the study at investigator's discretion
Patients who refuse to participate
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eun Bong Lee, MD PhD
Organizational Affiliation
Seoul National University College of Medicine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jin Kyun Park, MD
Organizational Affiliation
Seoul National University Hospital
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Yun Jong Lee, MD PhD
Organizational Affiliation
Seoul National Universty Bundang Hospital
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Kichul Shin, MD PhD
Organizational Affiliation
SMG-SNU Boramae Medical Center
Official's Role
Study Director
Facility Information:
Facility Name
Seoul National Univ. Bundang Hospital
City
Bundang
State/Province
Gyeonggi-do
ZIP/Postal Code
463-870
Country
Korea, Republic of
Facility Name
Seoul National University Hospital
City
Seoul
ZIP/Postal Code
110-744
Country
Korea, Republic of
Facility Name
SMG-SNU Boramae Medical Center
City
Seoul
ZIP/Postal Code
156-707
Country
Korea, Republic of
12. IPD Sharing Statement
Citations:
PubMed Identifier
24468932
Citation
Kloppenburg M. Hand osteoarthritis-nonpharmacological and pharmacological treatments. Nat Rev Rheumatol. 2014 Apr;10(4):242-51. doi: 10.1038/nrrheum.2013.214. Epub 2014 Jan 28.
Results Reference
background
PubMed Identifier
23474153
Citation
Shin K, Kim JW, Moon KW, Yang JA, Lee EY, Song YW, Lee EB. The efficacy of diacerein in hand osteoarthritis: a double-blind, randomized, placebo-controlled study. Clin Ther. 2013 Apr;35(4):431-9. doi: 10.1016/j.clinthera.2013.02.009. Epub 2013 Mar 6.
Results Reference
background
PubMed Identifier
22474519
Citation
Kim JK, Park SW, Kang JW, Kim YJ, Lee SY, Shin J, Lee S, Lee SM. Effect of GCSB-5, a Herbal Formulation, on Monosodium Iodoacetate-Induced Osteoarthritis in Rats. Evid Based Complement Alternat Med. 2012;2012:730907. doi: 10.1155/2012/730907. Epub 2012 Mar 4.
Results Reference
background
PubMed Identifier
15094138
Citation
Pham T, van der Heijde D, Altman RD, Anderson JJ, Bellamy N, Hochberg M, Simon L, Strand V, Woodworth T, Dougados M. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage. 2004 May;12(5):389-99. doi: 10.1016/j.joca.2004.02.001.
Results Reference
background
PubMed Identifier
22563589
Citation
Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, Towheed T, Welch V, Wells G, Tugwell P; American College of Rheumatology. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012 Apr;64(4):465-74. doi: 10.1002/acr.21596.
Results Reference
background
PubMed Identifier
23954277
Citation
Park YG, Ha CW, Han CD, Bin SI, Kim HC, Jung YB, Lim HC. A prospective, randomized, double-blind, multicenter comparative study on the safety and efficacy of Celecoxib and GCSB-5, dried extracts of six herbs, for the treatment of osteoarthritis of knee joint. J Ethnopharmacol. 2013 Oct 7;149(3):816-24. doi: 10.1016/j.jep.2013.08.008. Epub 2013 Aug 14.
Results Reference
background
PubMed Identifier
23726390
Citation
Coxib and traditional NSAID Trialists' (CNT) Collaboration; Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013 Aug 31;382(9894):769-79. doi: 10.1016/S0140-6736(13)60900-9. Epub 2013 May 30.
Results Reference
background
PubMed Identifier
27449412
Citation
Park JK, Shin K, Kang EH, Ha YJ, Lee YJ, Lee KH, Lee EY, Song YW, Choi Y, Lee EB. Efficacy and Tolerability of GCSB-5 for Hand Osteoarthritis: A Randomized, Controlled Trial. Clin Ther. 2016 Aug;38(8):1858-1868.e2. doi: 10.1016/j.clinthera.2016.06.016. Epub 2016 Jul 21.
Results Reference
derived
Learn more about this trial
Efficacy of Shinabro in Hand Osteoarthritis
We'll reach out to this number within 24 hrs